Q-omics provides the consensus-scored TRMT10B profile across patient tissues and cancer cell-line models. TRMT10B expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, TRMT10B is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, TRMT10B RNA expression shows 21,229 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BRCA, THCA, and UVM as cancer lineages where TRMT10B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRMT10B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRMT10B survival associations across molecular data types. TRMT10B RNA expression shows survival associations in the most cancer types (29), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRMT10B RNA expression–survival associations across cancer types. High TRMT10B expression shows unfavorable associations in ACC and MESO, but favorable associations in BRCA, PAAD, BLCA and THYM. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for TRMT10B RNA expression.
This table summarizes TRMT10B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for TRMT10B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRMT10B shows lower tumor expression in THCA and KICH and higher tumor expression in COAD, LIHC, CHOL and HNSC. The THCA box plot shows higher TRMT10B RNA expression in normal versus tumor tissue (log2 FC = −0.674, t-test p < 0.001).
This table shows molecular features associated with TRMT10B in patient tissues and cancer cell lines. In patient samples, TRMT10B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRMT10B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
